The CANVAS (Canagliflozin Cardiovascular Assessment Study) trial provided the opportunity to determine the utility of measuring cardiorenal biomarkers, such as fibroblast growth factor 23 (FGF-23) and high-sensitivity C-reactive protein (hsCRP) levels for determining risk prediction and treatment response to sodium glucose co-transporter 2 inhibitor therapy in patients with type 2 diabetes mellitus. Here, CRP is linked to type 2 diabetes mellitus.